SCHEMBL5727353

SCHEMBL5727353

C[C@H](C(=O)Cl)c1ccc(NC(=O)O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.45
KIF11 P52732 1/20 0.42
MAPT P10636 6/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 3/20 0.42
CRHBP P24387 2/20 0.42
CRHR2 Q13324 2/20 0.42
LMNA P02545 2/20 0.42
GAA P10253 1/20 0.42
NPC1 O15118 1/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
HPGD P15428 1/20 0.40
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
EGFR P00533 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7479983 0.85 NR1H4 (0.59) NR1H4KIF11MAPTSMN1; SMN2CRHBP
SCHEMBL9257901 0.82 PTGS2 (0.46) LMNATSHRPTGS2
SCHEMBL1027400 0.80 KIF11 (0.61) KIF11MAPTSMN1; SMN2RAB9ACRHBP
SCHEMBL28905039 0.80 KIF11 (0.47) NR1H4KIF11MAPTSMN1; SMN2RAB9A
SCHEMBL4088865 0.79 EGFR (0.48) NR1H4KIF11MAPTSMN1; SMN2RAB9A
SCHEMBL2415101 0.78 ALOX5 (0.46) MAPTSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL8956391 0.78 PTGS2 (0.61) LMNAHPGDALDH1A1RXFP1TSHR
SCHEMBL5726768 0.77 CYP17A1 (0.46) NR1H4SMN1; SMN2RAB9ANPC1HPGD
SCHEMBL5726733 0.77 CYP17A1 (0.46) NR1H4SMN1; SMN2RAB9ANPC1HPGD
SCHEMBL5726379 0.77 CYP17A1 (0.46) NR1H4SMN1; SMN2RAB9ANPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1724270-A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents Pfizer Italia S.r.l. (IT) 2006-11-22 EP disclosed
EP-1406899-B1 PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2006-11-15 EP disclosed
US-20040235919-A1 Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents PFIZER ITALIA S.R.I. (IT) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235919-A1 Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents CDK2, CDK1, CDKN1A NR1H4 3561/4885KIF11 1074/4885MAPT 2394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.